Dislipidemia market to slump 60% as cheap statins undercut new drugs
This article was originally published in Scrip
Sales of statins are forecast to drop from $13.7 billion in 2012 to $5.5 billion in 2021, despite retaining a 59% share of the dislipidemia patient population. The sales slump will be due to payers pushing for generic usage and the low switching costs associated with this, according to new analysis by Datamonitor Healthcare, Forecast: Dislipidemia .
You may also be interested in...
Three and a half months after Ionis Pharmaceuticals Inc. surprised investors with the news that Sanofi's Genzyme business unit would no longer market Kynamro (mipomersen) for homozygous familial hypercholesterolemia (HoFH), the Carlsbad, California-based biotechnology company revealed that it sold global rights to the cholesterol-lowering drug to Kastle Therapeutics LLC for up to $95m.
The UK's main reimbursement bodies made a series of decisions this week that were broadly favorable and largely focused on oncology medicines.
While troubled Valeant was divesting iNova to private equity investors, Novartis announced a pair of oncology-focused deals, out-licensing a brain cancer drug to Midatech and partnering with IBM Watson Health to optimize breast cancer treatment.